Foresight Initiates First Dosing In Viral Conjunctivitis Clinical Trial

Foresight has reported the dosing of first patient in a viral conjunctivitis clinical trial. Foresight’s lead compound, FST-100, will be tested in a placebo-controlled, masked, and randomized multicenter clinical study throughout the US.

The primary endpoint of the study is the resolution of clinical signs and symptoms of acute conjunctivitis, said the company.

The secondary endpoints include a reduction in quantitative PCR (qPCR) viral titers, and eradication of infectious virus determined by cell culture immunofluorescence assay (CC-IFA), and safety.

Reportedly, this controlled clinical trial follows a previously conducted successful pilot trial, in which the safety and efficacy of FST-100 were demonstrated.